Ethnobotanical significance of medicinal plants: Beta-amyloid and tau aggregation inhibitors against Alzheimer's disease

被引:6
|
作者
Ganapathy, A. Anand [1 ,2 ]
Haripriya, Vijayakumari M. M. [1 ,2 ]
Acharya, Niyati [3 ]
Somappa, Sasidhar B. B. [1 ,2 ]
Kumaran, Alaganandam [1 ,2 ]
机构
[1] CSIR Natl Inst Interdisciplinary Sci & Technol, Div Chem Sci & Technol, Thiruvananthapuram 695019, India
[2] Acad Sci & Innovat Res AcSIR, Ghaziabad, India
[3] Nirma Univ, Inst Pharm, Ahmadabad, Gujarat, India
关键词
Alzheimer's disease; beta-amyloid; ethnobotany; phytochemistry; tau; LONICERA JAPONICA THUNB; CLEAVING ENZYME 1; IN-VITRO; PROTEIN HYPERPHOSPHORYLATION; SCUTELLARIA-BAICALENSIS; FIBRIL FORMATION; GINSENOSIDE RD; GINKGO-BILOBA; PC12; CELLS; EXTRACT;
D O I
10.1002/jbt.23339
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Among the various neurodegenerative disorders, Alzheimer's disease (AD) is identified as one of primary causes of dementia in the elderly, which progresses slowly leading to cognitive decline and ability to function independently. Although various pathological mechanisms have been proposed, the exact mechanism is not yet elucidated. Numerous processes such as old age, mitochondrial dysfunction, and genetics lead to the aggregation of beta-amyloid (A beta) as amyloid plaques and tau proteins as neurofibrillary tangles in the neurons leading to their death and destruction, finally leading to AD. The current treatment measures can only temporarily improve the symptoms, slowing cognitive decline without any effect on AD pathology for better therapeutic effect. Furthermore, the high failure rates of a number of drugs during clinical trials due to their side effects has led the researchers to focus on alternative sources for drug development. As natural ingredients were considered the primary line of treatment in the olden days, and as several medicinal plant products are also proven as effective AD targets, it will be wise to investigate those with significant ethnobotanical value as potential neuroprotectives, nootropics or memory boosters. Throughout the study, propanoids, glycosides, iridoids, carotenoids and flavonoids that show potential anti-inflammatory, antioxidant, and anti-cholinesterase were also found to be inhibitors of A beta and tau aggregation, where Saikosaponin C, Fisetin, and Morin can act as dual inhibitors. The review provides an insight in the need for proper and complete scientific evaluation of these ethnobotanically useful medicinal plants to be identified as potential leads in AD therapy.
引用
收藏
页数:30
相关论文
共 50 条
  • [1] Cholinesterase inhibitors, beta-amyloid and Alzheimer's disease
    Lahiri, D
    Chen, DM
    Farlow, M
    Sambamurti, K
    Greig, N
    INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 157 - 157
  • [2] Vaccination against beta-amyloid in Alzheimer's disease
    Nitsch, RM
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S135 - S135
  • [3] Vaccination against beta-amyloid in Alzheimer's disease
    Nitsch, RM
    Hock, C
    JOURNAL OF NEUROIMMUNOLOGY, 2004, 154 (1-2) : 7 - 7
  • [4] First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimer's Disease
    Mariano, Marica
    Schmitt, Christian
    Miralinaghi, Parisa
    Catto, Marco
    Hartmann, Rolf W.
    Carotti, Angelo
    Engel, Matthias
    ACS CHEMICAL NEUROSCIENCE, 2014, 5 (12): : 1198 - 1202
  • [5] Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease
    Garcia-Font, Nuria
    Hayour, Hasna
    Belfaitah, Ali
    Pedraz, Jorge
    Moraleda, Ignacio
    Iriepa, Isabel
    Bouraiou, Abdelmalek
    Chioua, Mourad
    Marco-Contelles, Jose
    Jesus Oset-Gasque, Maria
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 118 : 178 - 192
  • [6] Novel beta-amyloid aggregate inhibitors for Alzheimer's disease
    Wong, R. M. S.
    Li, H. W.
    Kwong, D. W. J.
    Yung, K. K. L.
    Ke, Y.
    HONG KONG MEDICAL JOURNAL, 2019, 25 (04) : 26 - 29
  • [7] Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer's Disease
    Lee, Ni-Chung
    Yang, Shieh-Yueh
    Chieh, Jen-Jie
    Huang, Po-Tsang
    Chang, Lih-Maan
    Chiu, Yen-Nan
    Huang, Ai-Chiu
    Chien, Yin-Hsiu
    Hwu, Wuh-Liang
    Chiu, Ming-Jang
    FRONTIERS IN AGING NEUROSCIENCE, 2017, 8
  • [8] Apolipoprotein E, phosphorylated tau and beta-amyloid deposition in Alzheimer's disease
    Cairns, NJ
    Fukutani, Y
    Chadwick, A
    Lantos, PL
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1996, 22 (05) : 452 - 452
  • [9] Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease
    Zhang, Wei
    Smith, Nathan
    Zhou, Yiqun
    McGee, Caitlin M.
    Bartoli, Mattia
    Fu, Shiwei
    Chen, Jiuyan
    Domena, Justin B.
    Joji, Annu
    Burr, Hannah
    Lv, Guohua
    Cilingir, Emel K.
    Bedendo, Susanna
    Claure, Matteo L.
    Tagliaferro, Alberto
    Eliezer, David
    Veliz, Eduardo A.
    Zhang, Fuwu
    Wang, Chunyu
    Leblanc, Roger M.
    ACTA BIOMATERIALIA, 2024, 183 : 341 - 355
  • [10] Beta-amyloid immunisation in Alzheimer’s disease
    S. Sorbi
    Neurological Sciences, 2005, 26 : s5 - s5